The perplexities of conducting randomized, double-blind, placebo-controlled treatment trials in anorexia nervosa patients.
Halmi
Katherine A
KA
D000328:Adult; D000856:Anorexia Nervosa / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D015982:Bias; D015928:Cognitive Behavioral Therapy; D003631:Day Care, Medical / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009042:Motivation; D015337:Multicenter Studies as Topic; D009770:Obsessive Behavior / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D000077152:Olanzapine; D010349:Patient Compliance / Q000706:statistics & numerical data; D010352:Patient Dropouts / Q000523:psychology / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic; D016312:Treatment Refusal / Q000523:psychology / Q000706:statistics & numerical data; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine